Abstract
α-Crystallins, initially identified as the structural proteins of the ocular lens, belong to the small heat shock protein family. They play significant roles in maintaining the lens transparency and preventing protein aggregation. α-Crystallins exist in two isoforms: αA and αB, and they display differential tissue distribution. Their mutations are implicated in several human diseases including cardiac myopathies, neurodegenerative diseases, cataracts and various types of cancers. Increased αB expression was detected in retinoblastoma, breast cancer, glioblastoma, prostate and renal cell carcinomas, indicating its role in promoting tumor growth. A complex picture emerges for αA. Although earlier studies suggest that αA may promote cancer development, recent studies from our laboratory demonstrate that αA can act as a tumor suppressor inhibiting cell transformation and retarding cell migration through modulating MAP kinase activity. In this review, we summarize the recent progress about the functions of αA and αB in cancer development.
Keywords: αA, αB, cancer, crystallin, therapy.
Current Molecular Medicine
Title:Contrast Functions of αA- and αB-Crystallins in Cancer Development
Volume: 16 Issue: 10
Author(s): Z. Wang, L. Wang, Z.-X. Huang, X. Hu, J. Liu, W. Hu, W. Ji, Q. Nie, J.-W. Xiang, Z.-G. Chen, Y. Xiao, W.-J. Qiang, J. Zhu, J. W. Gigantelli, Q. D. Nguyen and D. W.-C. Li
Affiliation:
Keywords: αA, αB, cancer, crystallin, therapy.
Abstract: α-Crystallins, initially identified as the structural proteins of the ocular lens, belong to the small heat shock protein family. They play significant roles in maintaining the lens transparency and preventing protein aggregation. α-Crystallins exist in two isoforms: αA and αB, and they display differential tissue distribution. Their mutations are implicated in several human diseases including cardiac myopathies, neurodegenerative diseases, cataracts and various types of cancers. Increased αB expression was detected in retinoblastoma, breast cancer, glioblastoma, prostate and renal cell carcinomas, indicating its role in promoting tumor growth. A complex picture emerges for αA. Although earlier studies suggest that αA may promote cancer development, recent studies from our laboratory demonstrate that αA can act as a tumor suppressor inhibiting cell transformation and retarding cell migration through modulating MAP kinase activity. In this review, we summarize the recent progress about the functions of αA and αB in cancer development.
Export Options
About this article
Cite this article as:
Wang Z., Wang L., Huang Z.-X., Hu X., Liu J., Hu W., Ji W., Nie Q., Xiang J.-W., Chen Z.-G., Xiao Y., Qiang W.-J., Zhu J., Gigantelli W. J., Nguyen D. Q. and Li W.-C. D., Contrast Functions of αA- and αB-Crystallins in Cancer Development, Current Molecular Medicine 2016; 16 (10) . https://dx.doi.org/10.2174/1566524016666161223110508
DOI https://dx.doi.org/10.2174/1566524016666161223110508 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together
Current Drug Targets Dendrimer-Based Nanosized MRI Contrast Agents
Current Pharmaceutical Biotechnology Experimental Breast Cancer Models: Preclinical Imaging Perspective
Current Radiopharmaceuticals Zebrafish Stem Cell Differentiation Stage Factors Suppress Bcl-xL Release and Enhance 5-Fu-Mediated Apoptosis in Colon Cancer Cells
Current Pharmaceutical Biotechnology Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies: A Review
Current Clinical Pharmacology ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters 99mTc-(tricine)-HYNIC-Lys-FROP Peptide for Breast Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Meet the Editorial Board
Current Medicinal Chemistry Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry